Consolidated Investment Group LLC Buys 9,800 Shares of Zoetis Inc. $ZTS

Key Points

• Consolidated Investment Group LLC increased its Zoetis holdings by 59.6% during Q2, now owning 26,235 shares valued at approximately $4.1 million.
• Analyst ratings for Zoetis are mixed, with five analysts recommending a buy and five a hold, while the stock has an average target price of $200.88.
• In its latest earnings report, Zoetis surpassed analyst expectations with $1.76 earnings per share and revenue of $2.46 billion, marking a year-over-year revenue increase of 4.2%.

Consolidated Investment Group LLC grew its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 59.6% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 26,235 shares of the company's stock after purchasing an additional 9,800 shares during the quarter. Consolidated Investment Group LLC's holdings in Zoetis were worth $4,091,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. Lindbrook Capital LLC increased its stake in shares of Zoetis by 1.8% in the first quarter. Lindbrook Capital LLC now owns 3,715 shares of the company's stock worth $612,000 after purchasing an additional 65 shares during the period. Scott & Selber Inc. increased its stake in shares of Zoetis by 0.6% in the second quarter. Scott & Selber Inc. now owns 11,652 shares of the company's stock worth $1,817,000 after purchasing an additional 67 shares during the period. Secure Asset Management LLC increased its stake in shares of Zoetis by 2.9% in the second quarter. Secure Asset Management LLC now owns 2,448 shares of the company's stock worth $382,000 after purchasing an additional 68 shares during the period. Quotient Wealth Partners LLC increased its stake in shares of Zoetis by 2.3% in the first quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company's stock worth $521,000 after purchasing an additional 72 shares during the period. Finally, Broadway Wealth Solutions Inc. increased its stake in shares of Zoetis by 4.4% in the first quarter. Broadway Wealth Solutions Inc. now owns 1,746 shares of the company's stock worth $287,000 after purchasing an additional 73 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of recent analyst reports. Argus reiterated a "buy" rating and issued a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Weiss Ratings reissued a "hold (c-)" rating on shares of Zoetis in a research report on Saturday, September 27th. Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and decreased their target price for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and decreased their target price for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Finally, Piper Sandler lifted their target price on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Five investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, Zoetis presently has an average rating of "Moderate Buy" and a consensus target price of $200.88.

Zoetis Stock Down 0.0%

NYSE ZTS opened at $146.45 on Friday. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The stock's 50 day moving average is $149.79 and its two-hundred day moving average is $155.14. The company has a market capitalization of $64.91 billion, a price-to-earnings ratio of 25.21, a PEG ratio of 2.35 and a beta of 0.90. Zoetis Inc. has a 1-year low of $139.34 and a 1-year high of $196.55.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company's quarterly revenue was up 4.2% on a year-over-year basis. During the same period in the previous year, the business earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.